Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIA Study of the Safety and Tolerability of the Use of Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis

NCT00555581 is registered in ClinicalTrials.gov with Hospital for Special Surgery, New York as lead sponsor.

NCT NCT00555581
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00555581 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIA Study of the Safety and Tolerability of the Use of Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis
Lead sponsor
Hospital for Special Surgery, New York
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2007
Completion date
December 31, 2011
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

systemic sclerosis